Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Feel The Quality: Biosimilars Dominate Standards Setting Debate In EU

Executive Summary

The quality issues that the European Medicines Agency considers when it evaluates biosimilar medicines became clearer during a recent event held in Strasbourg, France, where delegates also learned more about the role of European Pharmacopoeia monographs in ensuring the quality of biosimilars.

You may also be interested in...



Biological Quality In The Spotlight As UK MHRA Consults On Standard-Setting

Quality standards for biological medicines are in the spotlight again, with the UK medicines regulator, the MHRA, in the midst of consulting stakeholders on how to ensure that publicly available monographs are suitable for biologicals in the future.

New European Monographs Set ‘Robust Standards’ For Biosimilar Development

A European Pharmacopoeia pilot project has resulted in the establishment of monographs for a number of complex biotherapeutics that will set “robust” standards for the development of biosimilars in the future.

Biosimilars Get Bespoke Service: EMA To Pilot Tailored Scientific Advice

Quality data will be focus of ‘extra advice’ offered by European Medicines Agency’s pilot, which will suggest directions for sponsors’ next steps but stop short of formal data evaluation.

Related Content

Topics

UsernamePublicRestriction

Register

LL055695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel